Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.